Join the Oncology Voice Network. Join for Free
The MSL Role - Big Pharma Vs. Small Biotech
MSL role differences large pharma vs small biotech career advice for MSLs MSL job market 2024 cultural differences in pharma

The MSL Role - Big Pharma Vs. Small Biotech


Share This Article


Summary

In this episode, Sarah Ussery joins to discuss her career journey and the distinctions between working in big pharma versus small biotech companies. Sarah provides an overview of both environments, highlighting the evolution of the MSL role and the responsibilities unique to each. She explores growth opportunities and the job market for both sectors, while addressing the challenges and cultural differences encountered in each setting. The conversation includes advice for MSLs navigating their careers in 2024, with insights on resume building and choosing between large pharma and small biotech. The episode concludes with closing remarks and a call to action.

My guest today is Sarah Ussery, Medical Affairs Leader who discusses the differences in MSL function between large pharma and small biotech.

  Sarah shares….

πŸ‘‰ What is considered Large Pharma VS Small Biotech
πŸ‘‰ How do MSL responsibilities differ by size of company
πŸ‘‰ How are MSLs evaluated differently by different companies
πŸ‘‰ How do the frustrations differ for MSLs in different size companies
πŸ‘‰ What are the cultural differences between different size companies

Click for Source
MSL role differences, large pharma vs small biotech, career advice for MSLs, MSL job market 2024, cultural differences in pharma

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Press Release
Visionaries Behind Oncology Voice Network: Dr. Ramin Farhood & Dr. Kirk Shepard
OVN Avatar OVN Staff

Visionaries Behind Oncology Voice Network: Dr. Ramin Farhood & Dr. Kirk Shepard

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Podcast
The Ideal Roadmap for New MSLs
Partner Avatar MSL Talk: Tom Caravela, Sarah Snyder

The Ideal Roadmap for New MSLs

Explore OVN